Navigation Links
PharmaNet/i3 Renamed inVentiv Health Clinical

BURLINGTON, Mass., Jan. 30, 2013 /PRNewswire/ -- inVentiv Health, Inc., offering best-in-class clinical, commercial, and consulting services to the healthcare industry, today announced that its existing clinical research organization (CRO), PharmaNet/i3, will be renamed inVentiv Health Clinical.  This renaming reflects the closer alignment between the Clinical segment and inVentiv's commercial and consulting services.

"As a top global CRO, renaming ourselves inVentiv Health Clinical demonstrates a company-wide commitment to our clinical clients, who will benefit from seamless, global access to a more robust range of services," said Paul Meister , Chief Executive Officer at inVentiv Health.  "Clients can now access broad inVentiv talent with expertise across the product life cycle to deliver tailored solutions from product development through commercialization."

Industry veteran Raymond Hill was appointed in December to lead inVentiv Health Clinical.  Prior to joining inVentiv, Hill was CEO at Pharmaceutical Product Development, Inc., where he successfully oversaw the process of taking the company private.  Before that, Hill was President at IMS Consulting Group, where he oversaw an aggressive strategy of organic and inorganic growth – building the business to $500M in six years.  Hill is a graduate of Cornell University and holds a master's degree from Duke University.

"By connecting clinical research and staffing capabilities to consulting and commercial services, inVentiv can offer fully integrated solutions to pharmaceutical, biotechnology, generic drug and medical device companies in a way that cannot be matched by any other CRO in the industry," said Hill.  "One example is our ability to assist clients in Late Stage trials by tapping both digital and adherence experts from other inVentiv companies.  Through this approach we can help our clients simplify complex health economics and outcomes research trials."

inVentiv Health Clinical is a leading clinical research organization offering Early Stage (Phase I), Phase II-III, Late Stage (Phase IV) clinical development and clinical staffing services to healthcare companies worldwide.  These services can be deployed on any scale from highly complex multinational clinical trials to earlier stage studies involving specialized patient populations to Late Stage post-approval studies, or from placing a single individual at a company to outsourcing a full clinical department. 

"Healthcare companies are continuing to increase their reliance on CROs," said Hill.  "With 7,000 employees in more than 36 countries across the world, inVentiv Health Clinical has the breadth of experience in geographies and the necessary therapeutic expertise to meet the challenges that our clients are facing."

About inVentiv Health Clinical
inVentiv Health Clinical, formerly PharmaNet/i3, is a leading provider of global drug development services to pharmaceutical, biotechnology, generic drug, and medical device companies, offering therapeutically specialized capabilities for Phase I-IV clinical development, bioanalytical services, and strategic resourcing from a single clinical professional to an entire functional team.  With 7,000 passionate employees in more than 36 countries, inVentiv Health Clinical works to accelerate high quality drug development programs of all sizes around the world.

About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv offers convergent services that deliver extraordinary outcomes to clients whose goal is improving human life.  In 40 countries around the world, inVentiv's 13,000 employees help clients rapidly transform promising ideas into commercial reality.  inVentiv clients include more than 550 pharmaceutical, biotech and life sciences companies, as well as companies that now see health as part of their mission.  inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team.  For more information, visit   

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of the consummation of any announced and future acquisitions; the impact of any change in our ratings and the ratings of our debt securities on our relationships with customers, vendors and other third parties; the impact of any additional leverage we may incur on our ratings and the ratings of our debt securities; our ability to sufficiently increase our revenues and maintain or decrease expenses and cash capital expenditures to permit us to fund our operations; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact of pricing pressures on pharmaceutical manufacturers from future healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and achieve the resulting synergies; the resolution of purchase price adjustment disputes in connection with our recent acquisitions and related impacts; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base; our ability to comply with all applicable laws as well as our ability to successfully implement from a timing and cost perspective any changes in applicable laws; our ability to recruit, motivate and retain qualified personnel, including sales representatives; the possibility that client agreements will be terminated or not renewed; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; the impact of customer project delays and cancellations; our ability to convert backlog into revenue; the potential liability associated with injury to clinical trial participants; the actual impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memoranda provided in connection with the issuance of our notes for further discussion of these risks and other factors.

SOURCE inVentiv Health, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. PharmaNet/i3 Introduces PharmaNet/i3 Strategic Resourcing
2. PharmaNet/i3 Receives Distinguished Partner Award from the US Chinese Anti-Cancer Association
3. inVentiv Health Strengthens Clinical Leadership Team
4. inVentiv Medical Management Forms Partnership with Vital Decisions
5. The Female Health Company Reports Record First Quarter FY2013 Operating Results
6. Genomic Health to Announce Fourth Quarter and Year-End 2012 Financial Results and Host Conference Call on Wednesday, February 6, 2013
7. Natural Tree Extract (Larch Arabinogalactan) Shown to Have Statistically Significant Effect in Protecting Immune Health
8. RedBrick Healths New Approach to Health Engagement and Behavior Change Propels Record Growth in its Employee Health and Wellness Business
9. Indian Pharmaceutical Market Outlook - Enhanced purchasing power, rural market penetration and expanded access to healthcare attracting Big Pharma investment
10. Randy Gaboriault of Christiana Care Health System Named Computerworld Premier 100 IT Leader
11. Hologic to Showcase 3D Mammography and Other Recent Innovations in Healthcare at the 38th Arab Health Congress in Dubai
Post Your Comments:
(Date:11/27/2015)... ) ... "2016 Global Tumor Marker Testing Market: Supplier ... Segment Forecasts, Innovative Technologies, Instrumentation Review, Competitive ... offering. --> ) has ... Global Tumor Marker Testing Market: Supplier Shares ...
(Date:11/26/2015)... , Países Bajos, November 26, 2015 ... terapia fotodinámica de Bremachlorin para el cáncer avanzado. ... inmunoterapia con la terapia fotodinámica de Bremachlorin para el ... nuevo enfoque combina la inmunoterapia con la terapia fotodinámica ... Clinical Cancer Research . --> Clinical ...
(Date:11/26/2015)... , November 26, 2015 ... new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy for ... combination approach blends immunotherapy with Bremachlorin-photodynamic therapy for advanced ... combination approach blends immunotherapy with Bremachlorin-photodynamic therapy for advanced ... has found that immunotherapy can be efficiently combined ...
Breaking Medicine Technology:
(Date:11/27/2015)... , ... November 27, 2015 , ... Avid collector, Andrew ... Arbor Michigan boxing style concert posters. This is one of Joplin's most famous and ... House at the University of Michigan in Ann Arbor. The According to Hawley, "It ...
(Date:11/26/2015)... ... November 26, 2015 , ... Inevitably when people think Thanksgiving, they also ... buy during the Black Friday and Cyber Monday massage chair sales to ... Internet high and low to find the best massage chair deals, they can see ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... ... of workshops to discuss bioavailability and the need to integrate dose form selection ... in collaboration with OBN, the membership organization supporting and bringing together the UK’s ...
(Date:11/26/2015)... ... November 26, 2015 , ... WorldCare International, ... in the 61st annual Employee Benefits Conference. The Employee Benefits Conference was hosted ... 8th through Wednesday, November 11th, 2015. The conference was held at the Hawaii ...
(Date:11/26/2015)... ... 2015 , ... Indosoft Inc., developer and distributor of the world-class Asterisk based ... efficiency and reliability. , The new Q-Suite 6 platform is based on the latest ... itself into a specific piece of software for many key components of the suite. ...
Breaking Medicine News(10 mins):